Phase I Study in Advanced Solid Tumors

IBL1002:Phase I Study of Indibulin in Advanced Solid Tumors

Dose escalating study of orally administered indibulin at twice daily schedule in subjects with solid tumors.

Study Overview

• Status: Unknown
• Conditions: Solid Tumors
• Intervention / Treatment: Drug: indibulin

• Study Type: Interventional
• Enrollment (Actual): 22
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Santa Monica, California, United States

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria

1. Subjects with histological or cytological confirmation of advanced cancer, refractory to standard therapies for their condition
2. ≥ 18 years of age
3. ECOG performance score ≤ 2 (see Appendix 3)
4. Eligible subjects MUST have at least one measurable lesion as defined by RECIST guidelines (See Appendix 4). If the measurable disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology. Measurable lesions MUST not have been in a previously irradiated field or injected with biological agents.
5. Life-expectancy ≥ 12 weeks

6. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted < 2 weeks prior to Baseline:

   • Creatinine ≤ 1.5 X upper limit of normal (ULN) OR a calculated creatinine clearance ≥ 50 cc/min
   • Total bilirubin ≤ 1.5 X ULN
   • Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 X ULN
   • White blood cell count ≥3.0 x 109/L
   • Absolute Neutrophil Count (ANC) ≥1.5 x 109/L
   • Platelets ≥100 x 109/L
   • Hemoglobin ≥ 10 g/dL
7. Written informed consent in compliance with ZIOPHARM policies and the Human Investigation Review Committee with jurisdiction over the site.

Exclusion Criteria

1. New York Heart Association (NYHA) functional class ≥3 or myocardial infarction within 6 months (see Appendix 5)
2. Uncontrolled cardiac arrhythmia other than asymptomatic atrial fibrillation
3. Pregnant and/or lactating female (a reliable method of contraception must be used in all men and in women of childbearing potential during the study and for 3 months after last study drug administration).
4. Uncontrolled systemic infection (documented with microbiological studies)
5. Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study entry. Mitomycin C or nitrosureas should not be given within 6 weeks of study entry.
6. Radiotherapy during the study or within 3 weeks of study entry
7. Surgery within 4 weeks of start of study drug excluding tumor biopsy for pharmacodynamic parameters
8. Investigational drug therapy outside of this trial during or within 4 weeks of study entry
9. History of an invasive second primary malignancy diagnosed within the previous 3 years except for Stage I endometrial/cervical carcinoma or prostate carcinoma treated surgically, and non-melanoma skin cancer
10. Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results
11. Any condition that is unstable or which could jeopardize the safety of the subject and his/her compliance with the study protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Single Arm	Drug: indibulin; Dose escalation of indibulin given twice daily for up to 6 months; Other Names: ZIO-301

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
toxicities	6 months

Secondary Outcome Measures

Outcome Measure	Time Frame
pharmacokinetics	6 months

Collaborators and Investigators

• Sponsor: Alaunos Therapeutics
• Investigators: Study Director: Jonathan Lewis, MD, Alaunos Therapeutics

Publications and helpful links

General Publications

• Kapoor S, Srivastava S, Panda D. Indibulin dampens microtubule dynamics and produces synergistic antiproliferative effect with vinblastine in MCF-7 cells: Implications in cancer chemotherapy. Sci Rep. 2018 Aug 17;8(1):12363. doi: 10.1038/s41598-018-30376-y.

Study record dates

Study Major Dates

• Study Start: June 1, 2007
• Primary Completion (Anticipated): June 1, 2013
• Study Completion (Anticipated): June 1, 2013

Study Registration Dates

• First Submitted: December 26, 2007
• First Submitted That Met QC Criteria: December 26, 2007
• First Posted (Estimate): January 11, 2008

Study Record Updates

• Last Update Posted (Estimate): July 19, 2012
• Last Update Submitted That Met QC Criteria: July 18, 2012
• Last Verified: July 1, 2012

More Information

Terms related to this study

• Keywords: cancer; solid tumor; tumor; advanced tumor
• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: IBL1002